Bronchiolitis Obliterans Syndrome Pipeline Insight, 2020 by DelveInsight

Bronchiolitis Obliterans Syndrome Pipeline Insight, 2020 by DelveInsight

DelveInsight has launched a new report on Bronchiolitis Obliterans Syndrome Pipeline

Bronchiolitis obliterans syndrome (BOS) is a form of chronic lung allograft dysfunction that affects a majority of lung transplant recipients and is the primary factor limiting long-term transplant survival. It is characterized by progressive airflow obstruction resulting in acute rejection of the graft, followed by infections, or other coexistent condition.

Request for free sample copy-

Bronchiolitis Obliterans Syndrome Pipeline analysis across different stages of development (Phase III), different emerging trends, and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities

Bronchiolitis Obliterans Syndrome Emerging Therapy

The expected launch of emerging therapy such as Liposomal Cyclosporine A (Zambon Pharma), Ruxolitinib (Incyte Corporation), Pirfenidone (Genentech) is expected to change the treatment landscape of Bronchiolitis Obliterans Syndrome (BOS) in the upcoming years.

Emerging drugs included in the report

  • Liposomal Cyclosporine A: Zambon Pharma
  • Ruxolitinib: Incyte Corporation
  • Pirfenidone: Genentech

Bronchiolitis Obliterans Syndrome Drugs

Bronchiolitis Obliterans Syndrome Treatment includes the use of Leukotriene Receptor Antagonist, Anti-Fibrotic Agents, Cell-cycle Inhibitors, Macrolide Antibiotics followed by Induction Therapies to avoid acute rejection at the time of transplantation.

Bronchiolitis Obliterans Syndrome Treatment

Despite rapid advances in the discipline of lung transplantation and demonstrable improvement in short-term outcomes, there has been no substantial decrease in the prevalence of BOS, and no effective treatment has yet been established. This results into BOS being the principal factor contributing to limited long-term survival and suboptimal quality of life among lung allograft recipients and represents a major scientific challenge that must be surmounted before lung transplantation can become a durable, curative therapy for patients with advanced lung disease.

Bronchiolitis Obliterans Syndrome Report Highlights

  • The companies and academics are working to assess challenges and seek opportunities that could influence Bronchiolitis Obliterans Syndrome R&D. The therapies under development are focused on novel approaches to treat/improve Bronchiolitis Obliterans Syndrome.
  • In January 2020, Altavant Sciences acquired Onspira Therapeutics. The Company is intended to develop OSP-101 for the treatment of Bronchiolitis Obliterans Syndrome, the leading cause of morbidity and mortality in post-lung transplant patients.
  • In May 2017, PARI Pharma gained Orphan Drug Designation for L CsA i for the treatment of BOS by the European Commission. L-CsA-i has also received Orphan Drug Designation from the FDA for the treatment of bronchiolitis obliterans.
  • Breath Therapeutics’ drug device platform consists of liposomal drug-aerosol formulations and cutting-edge inhalation technology. The basis for successful inhalation therapy is precise and fast drug delivery into the small airway of the lungs. This requires a uniquely designed drug formulation paired with a high-performance, drug-specific nebulizer.
  • In August 2014, Roche and InterMune reach a definitive merger agreement in which Roche acquired InterMune for USD 74.00 per share. This corresponds to a total transaction value of US$ 8.3 billion on a fully diluted basis. This offer represents a premium of 38% to InterMune’s closing price on 22 August 2014 and a premium of 63% to InterMune’s unaffected closing price on 12 August 2014. The merger agreement has been approved by the boards of InterMune and Roche.
  • In October 2017, Mereo BioPharma acquired an exclusive license for MPH-966 from AstraZeneca together with an option to acquire the IP based on certain milestones.


Request for free sample copy-

Table of content

  • Introduction
  • Executive Summary
  • Bronchiolitis Obliterans Syndrome: Overview
  • Pipeline Therapeutics
  • Therapeutic Assessment
  • Bronchiolitis Obliterans Syndrome – DelveInsight’s Analytical Perspective
  • In-depth Commercial Assessment
  • Bronchiolitis Obliterans Syndrome Collaboration Deals
  • Late Stage Products
  • Mid Stage Products
  • Early Stage Products
  • Pre-clinical and Discovery Stage Products
  • Inactive Products
  • Bronchiolitis Obliterans Syndrome Key Companies
  • Bronchiolitis Obliterans Syndrome Key Products
  • Bronchiolitis Obliterans Syndrome- Unmet Needs
  • Bronchiolitis Obliterans Syndrome- Market Drivers and Barriers
  • Bronchiolitis Obliterans Syndrome- Future Perspectives and Conclusion
  • Bronchiolitis Obliterans Syndrome Analyst Views
  • Bronchiolitis Obliterans Syndrome Key Companies
  • Appendix


What are the key questions answered?

  • How many companies are developing Bronchiolitis Obliterans Syndrome drugs?
  • How many Bronchiolitis Obliterans Syndrome drugs are developed by each company?
  • How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Bronchiolitis Obliterans Syndrome?
  • What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Bronchiolitis Obliterans Syndrome therapeutics?
  • What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Bronchiolitis Obliterans Syndrome and their status?
  • What are the key designations that have been granted to the emerging drugs?

Related Reports


Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: +919650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States